Biokine Therapeutics Announces Issuance of United States Patent

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

Biokine Therapeutics Announces Issuance of United States Patent2021-06-03T06:16:35+00:00

Biokine Therapeutics Announces Issuance of Chinese Patent covering the composition and use of novel chemokine binding polypeptides

Biokine Therapeutics Announces Issuance of Chinese Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

Biokine Therapeutics Announces Issuance of Chinese Patent covering the composition and use of novel chemokine binding polypeptides2021-06-03T06:13:12+00:00

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of peptides for inhibiting chemokine binding to chemokine receptors

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of peptides for inhibiting chemokine binding to chemokine receptors (BKT130 Project).

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of peptides for inhibiting chemokine binding to chemokine receptors2021-06-03T06:12:26+00:00

BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment

BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment The results from the phase 1 trial expected by end of 2014 or early 2015. BKT-140/BL-8040 is also in the midst of a Phase 2 trial for AML, with results expected in early 2015.

BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment2021-06-03T06:12:09+00:00

Biokine Announces Issuance of Mexican Patent

Biokine Therapeutics Announces Issuance of Mexican Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

Biokine Announces Issuance of Mexican Patent2021-06-03T06:05:52+00:00

Biokine Announces Issuance of European Patent

Biokine Therapeutics Announces Issuance of European Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

Biokine Announces Issuance of European Patent2021-06-03T06:05:30+00:00
Go to Top